2 new compounds show promise for eliminating breast cancer tumorsNovember 19, 2008Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors. Associate Professor James Turkson's compounds disrupt the formation and spread of breast cancer tumors in tests on mice. The compounds, S3I-201 and S3I-M2001, break up a cancer-causing protein called STAT3, and researchers have observed no negative side effects so far. "The compounds are very promising," Turkson said. "They've worked very well in mice, and now we're looking for partners to help us take these compounds to the next level of trials."
Turkson's research has been published in the academic journals Proceedings of the National Academy of Sciences and ACS Chemical Biology, and he has obtained patents for both compounds. Turkson is passionate about his research and has a very personal reason for wanting to find a cure for cancer. During his first year of college, his 52-year-old mother was diagnosed with uterine cancer and died. He dedicated his life to finding a cure. The two compounds developed in his lab hold promise in part because they efficiently disrupt the abnormally active STAT3 protein he said. "We all have the STAT3 protein in our bodies, and under normal circumstances it causes no harm. But in breast cancer patients, the protein is abnormally active. It never shuts off." When that happens, the protein goes into overdrive and is bent on supporting the proliferation of breast cancer cells. The protein even creates a network of blood vessels to feed the cancer cells, support their growth and eventually promote the spread of the cancer into the blood, bones and organs. "Our compounds go after STAT3, stripping away its power," Turkson said. Both compounds disrupt the bonding process that one STAT3 molecule goes through to connect with another in the body. If the STAT3 can't bond to stay abnormally-active, cancer cells can't develop. The network of blood vessels that formed to feed the cancer cells also shuts off. Left without their source of food, the existing cancer cells die off. The body's immune system, which until now has been tricked by the abnormally active STAT3 into thinking the tumor cells are harmless, also recognizes that something is wrong. The immune system re-activates, recognizes any remaining cancer cells as harmful and destroys them. Turkson worked with researchers at the H. Lee Moffitt Cancer Center and Research Institute, and the Beckman Research Institute and the Comprehensive Cancer Center of the City of Hope National Medical Center. Turkson is a native of Ghana, West Africa. He completed his studies and obtained his honors B.S. degree in Biochemistry with Chemistry at the University of Ghana. He earned a Ph.D. in Pharmacology from the University of Alberta in Canada. He completed post-doctoral fellow training in Molecular Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, where he served as an assistant professor before joining UCF's Burnett School of Biomedical Sciences in 2005. While Turkson continues to look for partners to further his research, he's already working on a similar compound for pancreatic cancer. In that case the compound would enhance the potency of another drug and use the body's immune system to make the effect more powerful. University of Central Florida Science News and Science Current Events Tag Cloud This tag cloud is a visual representation of term frequencies of random science news topics with common terms grouped together and emphasized by their display size. Childhood Cancer Medulloblastoma Collagen Neuroticism Body Temperature Infection Water Molecules Ear Infections Stroke Damage Predators Heart Disease Kidney Function Drinking Water Abortion Amphibians Phytophthora Influenza Vaccine Sleeping Sickness Trauma Abdominal Pain Cognition Endometriosis Caesarean Section Sturgeon Caesarean
See More: Science News Tags | |||||||||||||||||||||
|
Related Cancer Cells Current Events and Cancer Cells News Articles Newly appreciated membrane estrogen receptor important therapeutic target for breast cancer New research at Rhode Island Hospital has uncovered the biological effects of a novel membrane estrogen receptor, a finding that has potential implications for hormonal therapy for breast cancer. Researchers testing virus-gene therapy combination against melanoma Researchers at the Moores UCSD Cancer Center are injecting a modified herpes virus into melanoma tumors, hoping to kill the cancer cells while also bolstering the body's immune defenses against the disease. Predicting the return of prostate cancer: New Johns Hopkins study betters the odds of success Cancer experts at Johns Hopkins say a study tracking 774 prostate cancer patients for a median of eight years has shown that a three-way combination of measurements has the best chance yet of predicting disease metastasis. Study shows PET can measure effectiveness of novel breast cancer treatment A new study published in the July issue of The Journal of Nuclear Medicine shows that positron emission tomography (PET) scans in mice can be used to determine whether a novel type of breast cancer treatment is working as intended. Novel epigenetic markers of melanoma may herald new treatments for patients Melanoma is the most serious form of skin cancer, diagnosed in more than 50,000 new patients in the United States annually. While the rate of incidences continues to rise, survival rate has not improved and the race is on to find the genetic and cellular changes driving melanoma and to devise new means of detection and treatment. Insulin analogue glargine possibly increases cancer risk The risk of cancer possibly increases if patients with diabetes use the long-acting insulin analogue glargine instead of human insulin. Researchers pinpoint a new enemy for tumor-suppressor p53 Researchers at The University of Texas M. D. Anderson Cancer Center have identified a protein that marks the tumor suppressor p53 for destruction, providing a potential new avenue for restoring p53 in cancer cells. Effective pain treatment for cancer patients? Cancer patients often suffer from severe pain that cannot be effectively treated with conventional medication. Like burrs on your clothes, molecule-size capsules can deliver drugs by sticking to targeted cells It is now possible to engineer tiny containers the size of a virus to deliver drugs and other materials with almost 100 percent efficiency to targeted cells in the bloodstream. Cancer researchers link DICER1 gene mutation to rare childhood cancer Research published today in Science Express from the journal Science demonstrates the first definitive link between mutations in the gene DICER1 and cancer. More Cancer Cells Current Events and Cancer Cells News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||